Abstract: Provided for herein is a polynucleotide-modified bioconjugate comprising a substrate such as an antibody or bead linked to a conjugate component via a nucleic acid linker. Also provided are methods of making and using such bioconjugates. Conjugation methods for creating the bioconjugate are stable, not chemically harsh, and efficient enough that post-conjugation purification may not be required. Further this disclosure provides for reducing the logistic overheads related to product lines by eliminating the need for many unique linkers per conjugation pair.
Type:
Grant
Filed:
December 7, 2021
Date of Patent:
February 24, 2026
Assignee:
PHITONEX, Inc.
Inventors:
Craig Laboda, Michael Stadnisky, Christopher Dwyer, Nicholas Pinkin
Abstract: Provided for herein is a polynucleotide-modified bioconjugate comprising a substrate such as an antibody or bead linked to a conjugate component via a nucleic acid linker. Also provided are methods of making and using such bioconjugates. Conjugation methods for creating the bioconjugate are stable, not chemically harsh, and efficient enough that post-conjugation purification may not be required. Further this disclosure provides for reducing the logistic overheads related to product lines by eliminating the need for many unique linkers per conjugation pair.
Type:
Application
Filed:
November 9, 2023
Publication date:
May 16, 2024
Applicant:
Phitonex, Inc.
Inventors:
Craig Laboda, Michael Stadnisky, Christopher Dwyer